Ongoing Clinical Trials for Large Cell Lung Cancer Stage III
There are currently 2 ongoing clinical trials investigating new treatment approaches for Large Cell Lung Cancer Stage III. These studies are taking place in Germany, France, and Spain, testing immunotherapy combinations and personalized cell therapy approaches.
Clinical trial locations
- France
- Germany
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is investigating a combination treatment approach for large-cell neuroendocrine carcinoma of the lung, a serious and aggressive form of lung cancer. The study combines an immunotherapy medication called Atezolizumab with standard chemotherapy drugs including Carboplatin (or Cisplatin) and Etoposide. All medications are delivered directly into the bloodstream through intravenous infusion.
Main inclusion criteria: Patients must be at least 18 years old with a confirmed diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. If the cancer has mixed cell types, at least 50% must be this specific type. Participants must not have received previous systemic therapy, though those whose cancer returned at least 6 months after completing curative treatment may be eligible. An ECOG performance status of 0 to 2 is required, meaning patients should be reasonably active in daily life. The cancer must be measurable according to standard medical criteria, and patients must have adequate organ function, including appropriate liver enzyme levels, bilirubin, creatinine, neutrophil count, and platelet count.
Main exclusion criteria: Patients who have received any cancer treatment within the last 4 weeks cannot participate. Those with a history of severe allergic reactions to the study drugs, active infections requiring treatment, or other serious medical conditions that could interfere with the study are excluded. Pregnant or breastfeeding women cannot participate, nor can those who have participated in another clinical trial within the last 4 weeks. Patients with another type of cancer that has not been in remission for at least 5 years are excluded, as are those with brain metastases unless they have been treated and are stable. People with autoimmune diseases must be in stable condition to participate, and those with a history of drug or alcohol abuse within the last 12 months are excluded.
Main focus and goal: The primary goal of this study is to evaluate how effectively this combination of treatments works together in improving survival for patients with this aggressive type of lung cancer. Researchers will monitor how long patients live after starting treatment, track changes in cancer size, and observe how long it takes for cancer to begin growing again after treatment. The study will also carefully monitor any side effects participants experience to better understand both the effectiveness and safety of combining Atezolizumab with platinum-based chemotherapy and Etoposide.
Investigational drugs: Atezolizumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells by blocking proteins that help cancer cells hide. Platinum-based drugs (Carboplatin or Cisplatin) work by damaging the DNA of cancer cells to stop them from growing and dividing. Etoposide is a chemotherapy medication that interferes with DNA inside cancer cells to prevent them from dividing and growing.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial is exploring a personalized therapy approach for advanced non-small cell lung cancer using a new treatment called ATL001, which is a type of cell therapy. The study examines how ATL001 works both alone and in combination with pembrolizumab, an already-approved cancer medication. This represents a novel approach to targeting specific mutations found in cancer cells.
Main inclusion criteria: Patients must be between 18 and 75 years old with a life expectancy of at least 6 months at the time of tissue collection. They must have advanced non-small cell lung cancer that cannot be removed by surgery or has spread to other parts of the body, and the cancer must have either worsened after standard treatments or the patient cannot receive standard treatments due to side effects. The disease must be measurable according to specific medical guidelines, and patients must have a performance status of ECOG 0-1, meaning they are still relatively active. Before joining the study, patients must have been treated with a PD-1/PD-L1 inhibitor and experienced either disease progression or stable disease after at least four doses. The cancer must be smoking-related, and patients must be medically fit to undergo all study procedures, including blood and tumor tissue collection. Adequate organ function as shown by specific blood test results is required. Female patients of childbearing potential and male patients with female partners who can have children must agree to use effective birth control during and after treatment.
Main exclusion criteria: Patients with other types of cancer besides non-small cell lung cancer cannot participate. Those who are not within the specified age range, cannot follow study procedures, or have certain medical conditions or take medications that might interfere with the study are excluded. Pregnant or breastfeeding women cannot participate, nor can patients who have recently participated in another clinical trial. Those with a history of allergic reactions to the study drugs are also excluded.
Main focus and goal: The primary objective of this study is to assess the safety of ATL001 and how well patients tolerate it as a treatment. The trial will monitor patients over time to see how their cancer responds to the treatment and check for any side effects. Researchers will measure changes in tumor size and overall health outcomes, particularly how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new treatment options for patients with this condition.
Investigational drugs: ATL001 is a personalized cell therapy that uses specially designed immune cells called T cells to recognize and attack cancer cells. These T cells are created from the patient’s own tissue and are customized to target their specific cancer. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system detect and fight cancer cells by blocking a protein called PD-1, which normally prevents the immune system from attacking cancer cells. In this trial, the two are being tested together to see if the combination can improve treatment outcomes.
Summary
The two ongoing clinical trials for Large Cell Lung Cancer Stage III represent different approaches to treating advanced disease. One trial focuses specifically on large-cell neuroendocrine carcinoma using immunotherapy combined with traditional chemotherapy, while the other explores personalized cell therapy for non-small cell lung cancer more broadly. Both studies utilize immunotherapy approaches, reflecting the current trend in cancer research toward harnessing the body’s immune system to fight cancer.
The trials are concentrated in European countries, with Germany participating in both studies, while France and Spain are involved in the ATL001/pembrolizumab trial. Both studies target patients whose cancer has advanced beyond surgical treatment options and who have specific performance status requirements. The trials are expected to run until 2027 and 2029, providing important long-term data on these treatment approaches. These studies offer potential new treatment options for patients with limited alternatives, though it should be noted that they are still in the research phase and outcomes are not yet known.
